AxoGen ( (AXGN) ) has released its Q4 earnings. Here is a breakdown of the information AxoGen presented to its investors.
Axogen, Inc. is a leading company in the field of peripheral nerve repair, focusing on the development and commercialization of innovative surgical solutions to restore nerve function and improve patient quality of life. The company operates within the medical technology sector, providing a comprehensive portfolio of products for both scheduled and emergent nerve repair procedures.
Axogen, Inc. recently announced its financial results for the fourth quarter and full year of 2024, showcasing significant growth and improved financial performance. The company reported a 15.1% increase in revenue for the fourth quarter compared to the previous year, alongside a notable improvement in net income, transitioning from a loss to a profit.
Key financial highlights include a fourth-quarter revenue of $49.4 million and a full-year revenue of $187.3 million, reflecting a 17.8% increase from the prior year. The company’s gross margin remained strong at 75.8% for the year. Axogen also reported an adjusted EBITDA of $19.8 million for 2024, a significant improvement from the previous year’s loss. The company’s strategic focus on expanding its market presence and product adoption has contributed to these positive results.
Looking ahead, Axogen anticipates continued revenue growth in the range of 15% to 17% for 2025, with expectations of maintaining a strong gross margin. The company is also preparing for the potential approval of its Biologics License Application for the Avance Nerve Graft, which could further enhance its market position. Axogen remains committed to advancing its strategic objectives and expanding its role in the peripheral nerve repair market.